A novel anti-cancer therapy to target the Proviral Integration of the Moloney murine leukemia virus (PIM) kinases is available for licensing and co-development. PIM kinases are overexpressed in many solid cancers, which is predictive of poor survival in multiple cancer types. NIH inventors have
Whitney Hastings, Senior Technology Transfer Manager, National Cancer Institute, has been elected as Chair of the Federal Laboratory Consortium (FLC) Executive Board. Whitney will begin her term on October 1, 2023. She is succeeding Linda Burger as Chair. This will be the first time in the
Inventors at the National Institute of Dental and Craniofacial Research (NIDCR) have a technology available for licensing that could be used to treat cartilage damage caused by injuries, overuse, or disease. This technology includes a method for differentiating human induced pluripotent stem cells